Work

Safety and Efficacy of Ponatinib for Pulmonary Tumor Thrombotic Microangiopathy

Year: 2026

Type: article

Abstract: Background: We evaluated the safety and efficacy of ponatinib, a multi-target tyrosine kinase inhibitor, for pulmonary tumor thrombotic microangiopathy (PTTM). Methods and Results: We conducted a single-center, open-label, single-arm, prospective study; 3 patients associated with ovarian, breast, and gastric carcinomas were enrolled and received oral ponatinib for 2 weeks. All died from PTTM progression with no severe ponatinib-related adverse events. Conclusions: This study failed to demonstrate ponatinib efficacy. Further studies may evaluate the effect of different biochemical targets on PTTM.

Source: Circulation Reports

DOI: 10.1253/circrep.cr-26-0218